Normosang (Human Hemin)

Human Hemin, the active ingredient in Normosang, is a heme (heme analog) presented as a lyophilized powder for solution for injection for intravenous use. It treats acute intermittent porphyria in patients experiencing acute attacks.

GNH USA supplies Normosang as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Normosang provides heme replacement therapy for acute porphyria disorders, helping to control neurotoxic precursor buildup.

Acute intermittent porphyria: reduces accumulation of neurotoxic porphyrin precursors and alleviates acute attacks. Acute hepatic porphyria: supplies exogenous heme to suppress aminolevulinic acid synthase activity during crises. Porphyria‑related neurovisceral crises: restores heme levels to improve neurological symptoms. Variegate porphyria attacks: provides heme to reduce symptom severity.

Human Hemin may be associated with several adverse reactions, ranging from mild infusion‑related events to rare serious conditions.

Common Side Effects: - Infusion site pain or phlebitis - Nausea or vomiting - Headache - Fever or chills - Elevated liver enzymes - Mild hypotension

Serious or Rare Side Effects: - Anaphylactic or severe allergic reaction - Hemolysis, especially in patients with G6PD deficiency - Acute renal failure - Severe hypotension or shock

When using Normosang, clinicians should observe specific safety measures to minimize risks.

Monitor for hemolysis: assess hemoglobin and bilirubin levels, especially in G6PD‑deficient patients. Check liver function: perform baseline and periodic liver enzyme tests. Avoid rapid infusion: administer over the recommended period to reduce cardiovascular reactions. Use under specialist supervision: treatment should be managed by physicians experienced in porphyria care. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Human Hemin can interact with other medicines, influencing porphyria management or altering drug effects.

Major Interactions (Avoid): - Concomitant use of porphyrinogenic drugs (e.g., barbiturates, sulfonamides) may exacerbate porphyria attacks. - Co‑administration with phenobarbital can increase neurotoxic precursor accumulation.

Moderate Interactions (Monitor Closely): - Anticoagulants such as warfarin may have altered INR values; monitor coagulation. - Iron supplements may affect iron homeostasis; observe ferritin levels. - Live vaccines should be used with caution as immune response may be affected.